Development and characterization of lecithin stabilized glibenclamide nanocrystals for enhanced solubility and drug delivery

References

• Albanese A, Tang PS, Chan WC. (2012). The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu Rev Biomed Eng 14:1–16
   PubMed Web of Science ®Google Scholar
• Alkermes. (2012). “Nanocrystal Technology” company information. Available from: http://www.alkermes.com/ContractServices/Technologies/Bioavailability-Enhancement_e.pdf [last accessed 13 Feb 2012]
   Google Scholar
• Bunjes H, Unruh T. (2007). Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 59:379–402
   PubMed Web of Science ®Google Scholar
• Chen H, Khemtong C, Yang X, et al. (2011). Nanonization strategies for poorly water soluble drugs. Drug Discov Today 16:354–60
   PubMed Web of Science ®Google Scholar
• Coppack SW, Lant AF, McIntosh CS, et al. (1990). Pharmacokinetc and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Pharm 29:673–84
   Web of Science ®Google Scholar
• Dora CP, Singh SK, Kumar S, et al. (2010). Development and characterization of nanoparticles of glibencamide by solvent displacement method. Acta Pharma Drug Res 67:283–90
   PubMed Web of Science ®Google Scholar
• Du B, Shen G, Wang D, et al. (2013). Development and characterization of glimepiride nanocrystal formulation and evaluation of its pharmacokinetic in rats. Drug Deliv 20:25–33
   PubMed Web of Science ®Google Scholar
• Dufort S, Sancey L, Coll JL. (2012). Physico-chemical parameters that govern nanoparticles fate also dictate rules for their molecular evolution. Adv Drug Deliv Rev 64:179–89
   PubMed Web of Science ®Google Scholar
• Elbary AA, Salem HF, Maher ME. (2011). In vitro and in vivo evaluation of glibenclamide using surface solid dispersion (SSD) approach. Brit J Pharmacol Toxicol 2:51–62
   Google Scholar
• Elkordy AA, Jatto A, Essa E. (2012). In situ controlled crystallization as a tool to improve the dissolution of Glibenclamide. Int J Pharm 428:118–20
   PubMed Web of Science ®Google Scholar
• Faris NB, Müller RH. (2002). Nanocrystals for poorly soluble drugs for oral administration. Topics of PhD thesis and details on technologies, products, IP. New Drugs 2:20–1
   Google Scholar
• Fu Q, Sun J, Zhang D, et al. (2013). Nimodipine nanocrystals for oral bioavailability improvement: preparation, characterization and pharmacokinetic studies. Colloids Surf B Biointerfaces 109:161–6
   PubMed Web of Science ®Google Scholar
• Gao L, Liu G, Ma J, et al. (2012). Drug nanocrystals: In vivo performances. J Control Release 160:418–30
   PubMed Web of Science ®Google Scholar
• Gassmann P, List M. (1994). Hydrosols – alternatives for the parenteral application of poorly water soluble drugs. Eur J Pharm Biopharm 40:64–72
   Web of Science ®Google Scholar
• Göppert TM, Müller RH. (2005). Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 302:172–86
   PubMed Web of Science ®Google Scholar
• Gülsün T, Gürusoy RN, Öner L. (2009). Nanocrystal technology for oral delivery of poorly water soluble drugs. J Pharm Sci 34:55–65
   Google Scholar
• Ito F, Fujimori H, Honnami H, et al. (2008). Effect of polyethylene glycol on preparation of rifampicin-loaded PLGA microspheres with membrane emulsification technique. Colloids Surf B Biointerfaces 66:65–70
   PubMed Web of Science ®Google Scholar
• Jain S, Saraf S. (2010). Type 2 diabetes mellitus – its global prevalence and therapeutic strategies. Diabetes Metab Syndrome: Clin Res Rev 4:48–56
   Google Scholar
• Junghanns JU, Müller RH. (2008). Nanocrystal technology drug delivery and clinical applications. Int J Nanomed 3:295–309
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. (2007). Nanosizing – oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev 59:631–44
   PubMed Web of Science ®Google Scholar
• Kumari A, Yadav SK, Yadav SC. (2010). Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B Biointerfaces 75:1–18
   PubMed Web of Science ®Google Scholar
• Manimaran V, Damodaran N. (2010). Enhancement of dissolution rate of glibenclamide by solid dispersion technology. Int J Curr Pharm Res 2:14–17
   Google Scholar
• Melgardt MD, Porang A. (2009). Nanotechnology in drug delivery. New York: AAPS Press/Springer, 581–90
   Google Scholar
• Mohanraj VJ, Chen Y. (2008). Nanoparticles – a review. Trop J Pharm Res 5:561–73
   Google Scholar
• Müller RH, Gohla S, Keck CM. (2011). State of the art of nanocrystals – special features, production, nanotoxicology aspects and intracellular delivery. Eur J Pharm Biopharm 78:1–9
   PubMed Web of Science ®Google Scholar
• Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy, rationale for development and what we can expect for the future. Adv Drug Deliver Rev 47:3–19
   PubMed Web of Science ®Google Scholar
• Patravale VB, Date AA, Kulkarni RM. (2004). Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol 56:827–40
   PubMed Web of Science ®Google Scholar
• Rao S, Song Y, Peddie F, et al. (2012). Particle size reduction to the nanometer range a promising approach to improve buccal absorption of poorly water soluble drugs. Int J Nanomed 6:1245–51
   Web of Science ®Google Scholar
• Salazar J, Ghanem A, Müller RH, et al. (2012). Nanocrystals: comparison of the size reduction effectiveness of a novel combinative method with conventional top-down approaches. Eur J Pharm Biopharm 1:1–9
   Google Scholar
• Shaik R, Bilal AT. (2012). Nanomedicine current trends in diabetes management. Nanomed Nanotech 3:1–7
   Google Scholar
• Silke K, Rutledge EB, Piero M. (2012). Nanomedicine for treatment of diabetes in aging population: state of the art and future developments. Nanomed Nanotech Bio Med 8:S69–76
   PubMed Web of Science ®Google Scholar
• Sonke R, Albrecht S. (2013). Thermal degradation of amorphous glibenclamide. Eur J Pharm Biopharm 83:76–86
   PubMedGoogle Scholar
• Subedi RK, Kang KW, Choi HK. (2009). Preparation and characterization of solid lipid nanoparticles loaded with doxorubicin. Eur J Pharm Sci 37:508–13
   PubMed Web of Science ®Google Scholar
• Sun J, Wang F, Sui Y, et al. (2012). Effect of particle size on solubility, dissolution rate, and oral bioavailability: evaluation using coenzyme Q10 as naked nanocrystals. Int J Nanomed 7:5733–44
   PubMed Web of Science ®Google Scholar
• Tamara M. (2005). Soluble polymer conjugates for drug delivery. Drug Discov Today Tech 2:15–20
   PubMedGoogle Scholar
• Tom A, Max Z. (2012). Formulation technologies to overcome poor drug like properties. Drug Discov Today 9:e71–2
   Google Scholar
• Uner M, Yener G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomed 2:289–300
   PubMed Web of Science ®Google Scholar
• Wang AZ, Gu F, Zhang L, et al. (2008). Biofunctionalized targeted nanoparticles for therapeutic applications. Expert Opin Biol Ther 8:1063–70
   PubMed Web of Science ®Google Scholar
• Wei H, Lacan RR. (2006). Biorelevant dissolution media as predictive tool for glyburide a class II drug. Eur J Pharm Sci 19:45–62
   Google Scholar
• Wu L, Zhang J, Watanabe W. (2011). Physical and chemical stability of nanoparticles. Adv Drug Deliv Rev 63:456–69
   PubMed Web of Science ®Google Scholar
• Yu L, Li C, Le Y. (2011). Stabilized amorphous glibenclamide nanoparticles by high gravity technique. Mater Chem Phys 13:361–6
   Google Scholar
• Zheng N, Gao X, Song Q, et al. (2012). Lipid – based liquid crystalline nanoparticles as oral drug delivery vehicles for poorly water – soluble drugs: cellular interaction and in vivo absorption. Int J Nanomed 7:3703–18
   PubMed Web of Science ®Google Scholar